Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAUVAL vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Rauval (rauwolfia serpentina alkaloids) depletes catecholamines and serotonin from peripheral sympathetic nerve endings and the brain by binding to and inhibiting vesicular monoamine transporters (VMAT), thus reducing sympathetic outflow. This leads to vasodilation, decreased peripheral vascular resistance, and reduced blood pressure.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension (mild to moderate),Off-label: management of agitated states or psychiatric conditions (historically)
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
1.5 mg orally once daily, increased to 3 mg per day if needed. Maximum dose 6 mg per day.
250 mg orally twice daily
Terminal elimination half-life is 7-10 hours in normal renal function; prolonged to 14-20 hours in renal impairment, requiring dose adjustment.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Metabolized in the liver via CYP450 enzymes, primarily CYP3A4, to active and inactive metabolites.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
85-90% bound to albumin and alpha-1-acid glycoprotein.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
0.6-1.0 L/kg; indicates extensive extravascular distribution.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: 60-70% due to first-pass metabolism.
70-90% (oral); 100% (IV).
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, dose reduction by 50% is recommended.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Use with caution; maximum 1.5 mg daily.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Safety and efficacy not established in pediatric patients under 18 years.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Start at 1 mg orally once daily; consider slower titration due to increased sensitivity to orthostatic hypotension.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
May cause mental depression, especially at high doses, and should be discontinued if signs of depression appear.,Use with caution in patients with a history of peptic ulcer disease as it increases gastric acid secretion.,May cause orthostatic hypotension, tachycardia, and electrolyte disturbances.,Abrupt discontinuation may lead to withdrawal symptoms such as agitation, anxiety, and hypertension.
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to rauwolfia serpentina or any component,Active peptic ulcer disease,Ulcerative colitis,History of mental depression, especially with suicidal tendencies,Electroconvulsive therapy (ECT) within 7 days
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid tyramine-rich foods (aged cheeses, cured meats, fermented products) as rauwolfia may potentiate pressor effects. Limit salt intake to support blood pressure control. Grapefruit juice may increase drug levels; avoid concurrent consumption.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
First trimester: Increased risk of cardiovascular malformations. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and neonatal renal impairment.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Rauval is excreted in human milk; potential for serious adverse reactions in nursing infants. M/P ratio unknown. Breastfeeding is contraindicated.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
No established dose adjustments; use is contraindicated in pregnancy due to known teratogenicity and fetotoxicity.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Rauval (rauwolfia alkaloids) is an antihypertensive that depletes catecholamines. Avoid in patients with history of depression or peptic ulcer disease. Onset is slow (weeks), so not for hypertensive emergencies. Monitor for orthostatic hypotension, especially at initiation. May cause nasal congestion and bradycardia. Discontinue at least 2 weeks before elective surgery to avoid anesthetic interactions.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take exactly as prescribed; do not stop abruptly as it may cause rapid blood pressure increase.,Avoid driving or operating machinery until you know how this medication affects you, as it may cause dizziness or drowsiness.,Rise slowly from sitting or lying down to prevent falls due to low blood pressure.,Report any signs of depression, slow heartbeat, or unusual bruising/bleeding to your doctor.,Avoid alcohol, as it may worsen dizziness and drowsiness.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAUVAL vs ALDOCLOR-250, answered by our medical review team.
RAUVAL is a Antihypertensive that works by Rauval (rauwolfia serpentina alkaloids) depletes catecholamines and serotonin from peripheral sympathetic nerve endings and the brain by binding to and inhibiting vesicular monoamine transporters (VMAT), thus reducing sympathetic outflow. This leads to vasodilation, decreased peripheral vascular resistance, and reduced blood pressure.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAUVAL and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAUVAL is: 1.5 mg orally once daily, increased to 3 mg per day if needed. Maximum dose 6 mg per day.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAUVAL and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAUVAL is classified as Category C. First trimester: Increased risk of cardiovascular malformations. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and neonatal renal impairme. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.